[Muscle and bone health as a risk factor of fall among the elderly. Role of raloxifene in the prevention of osteoporotic fractures].
Accumulated evidence has clearly shown that the objective of osteoporosis lies in the prevention of osteoporotic fractures. This has led in recent years to therapeutic agents with prophylactic effects against osteoporotic fractures becoming widely used in the clinical setting as first-line agents for the treatment of osteoporosis. In this review, we provide an overview of the evidence accumulated to data on the effect of raloxifene in the prophylaxis of osteoporotic fractures. At present, evidence that supports the use of raloxifene for prophylaxis of non-vertebral fractures remains rather inadequate compared to that supports the use of bisphosphonates. However, there is mounting evidence that suggests the role of raloxifene in maintaining and improving bone structure, where raloxifene is shown to enhance bone strength by improving bone quality, suggesting its potential role in preventing non-vertebral fractures as well as in vertebral fractures.
Tokyo Women's Medical University, Department of Obstetrics and Gynecology.
Hiroaki
H
Ohta
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D006801:Humans; D010024:Osteoporosis / Q000150:complications*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016103:Spinal Fractures / Q000517:prevention & control*; D013131:Spine
D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride